CNSP — CNS Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for CNS Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 5 | 10.1 | 0.549 | 6.46 | 7.2 |
| Net Total Receivables | — | — | — | 0.883 | 0 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 7.48 | 12.6 | 1.59 | 8.66 | 8.1 |
| Net Property, Plant And Equipment | 0.016 | 0.006 | 0.005 | 0.006 | 0.018 |
| Other Long Term Assets | |||||
| Total Assets | 8.76 | 13.1 | 1.7 | 8.7 | 8.62 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 2.59 | 4.92 | 6.13 | 2.52 | 4.1 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 2.59 | 4.92 | 6.13 | 2.52 | 4.1 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 6.16 | 8.13 | -4.43 | 6.18 | 4.52 |
| Total Liabilities & Shareholders' Equity | 8.76 | 13.1 | 1.7 | 8.7 | 8.62 |
| Total Common Shares Outstanding |